Bispecific Antibody Cancer Therapy Global Market Report 2026

Bispecific antibody cancer therapy is a sophisticated immuno-oncology treatment strategy that utilizes engineered antibodies capable of binding simultaneously to two distinct antigens, typically one located on cancer cells and the other on immune cells. This dual-targeting action enables the immune system to identify and eliminate malignant cells more efficiently than conventional single-target antibody therapies. It is widely applied in precision oncology to improve therapeutic outcomes across multiple cancer types.

The primary mechanisms of bispecific antibody cancer therapy comprise T-cell engagers, natural killer cell engagers, checkpoint inhibitor bispecific, and antibody-drug conjugate bispecific hybrids. T-cell engagers are bispecific antibodies engineered to bind both cancer cells and T cells simultaneously, enabling targeted immune-mediated elimination of tumor cells. These therapies are utilized across multiple cancer indications, including hematologic malignancies, lung cancer, colorectal cancer, prostate cancer, and ovarian cancer. They are offered in formats such as immunoglobulin G-like bispecific, fragment-based bispecific T-cell engagers, nanobody-based formats, and trispecific constructs, serving end users including hospitals, specialty oncology centers, research and academic institutions, and pharmaceutical and biotechnology companies.

Tariffs are influencing the bispecific antibody cancer therapy market by increasing expenses related to imported biologic manufacturing inputs, advanced bioprocessing equipment, and specialized laboratory reagents essential for antibody engineering and production. This is resulting in delays in clinical trial supply chains and higher production costs, particularly in regions dependent on cross-border pharmaceutical sourcing such as Asia-Pacific and parts of Europe. Biomanufacturing-intensive segments like antibody-drug conjugate hybrids and trispecific antibody formats are most affected due to reliance on complex global supply networks. However, tariffs are also driving localization of biomanufacturing facilities, expansion of regional R&D activities, and increased investment in domestic biologics production ecosystems, strengthening long-term oncology innovation capabilities.

The bispecific antibody cancer therapy market size has grown exponentially in recent years. It will grow from $7.71 billion in 2025 to $9.48 billion in 2026 at a compound annual growth rate (CAGR) of 22.9%. The growth in the historic period can be attributed to increasing incidence of cancers such as colorectal cancer, growing utilization of monoclonal antibody therapies in oncology, expansion of immune checkpoint inhibitor adoption in clinical practice, growth in targeted cancer therapy research programs, advancement of early T-cell engager antibody platforms.

The bispecific antibody cancer therapy market size is expected to see exponential growth in the next few years. It will grow to $21.76 billion in 2030 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to increasing demand for precision immunotherapy solutions, growth in personalized oncology treatment approaches, rising investment in bispecific antibody pipeline development, expansion of combination immunotherapy regimens, and advancement in next-generation engineered antibody technologies for solid tumors. Major trends in the forecast period include expansion of trispecific antibody constructs for enhanced multi-antigen cancer targeting, increasing adoption of dual checkpoint inhibition bispecific therapies in solid tumors, rising development of nanobody-based bispecific platforms for improved tumor penetration, growth of antibody-drug conjugate bispecific hybrids for precision cytotoxic delivery, and advancement of personalized immuno-oncology regimens using engineered T-cell engager antibodies.

The increasing prevalence of cancer is expected to propel the growth of the bispecific antibody cancer therapy market going forward. Cancer refers to the uncontrolled proliferation and spread of abnormal cells within the body that can invade or destroy healthy tissues and may originate in almost any organ or tissue, with the potential to spread to other parts of the body through the blood and lymphatic systems. The prevalence of cancer is rising due to an aging population, as older individuals have a higher likelihood of developing cancer because of the gradual accumulation of genetic mutations and prolonged exposure to risk factors over time. Bispecific antibody cancer therapy enhances cancer treatment by simultaneously binding to cancer cells and immune cells, bringing them into close proximity to activate the immune system and improve the targeted elimination of tumor cells. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international public health organization, more than 35 million new cancer cases are projected in 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the bispecific antibody cancer therapy market.

Key companies operating in the bispecific antibody cancer therapy market are emphasizing the development of innovative treatments such as first-in-class bispecific T-cell engaging antibodies to enhance immune system recognition of cancer cells and address unmet needs in relapsed and refractory cancer cases. First-in-class bispecific T-cell engaging antibodies are advanced immunotherapy agents that simultaneously bind to cancer cells and T-cells, activating the immune system to directly eliminate tumor cells and improving targeted cancer cell destruction in patients with difficult-to-treat or relapsed malignancies. For example, in August 2023, Johnson & Johnson, a US-based healthcare and pharmaceutical company, obtained U.S. Food and Drug Administration (FDA) accelerated approval for TALVEY (talquetamab-tgvs), a first-in-class bispecific antibody therapy designed for adult patients with relapsed or refractory multiple myeloma who have received multiple prior lines of therapy. TALVEY is engineered to target both GPRC5D on multiple myeloma cells and CD3 on T-cells, enabling immune-mediated tumor cell killing. The therapy is administered via subcutaneous injection and uses step-up dosing to manage cytokine release syndrome, a commonly observed immune-related adverse effect.

In January 2026, AbbVie Inc., a US-based biopharmaceutical company, entered into a partnership with Remegen Co. Ltd. to jointly develop, manufacture, and commercialize RC148, a novel investigational PD-1/VEGF bispecific antibody for advanced solid tumors. Through this collaboration, AbbVie and Remegen aim to progress a new class of cancer treatment that enables the immune system to more effectively attack tumors by concurrently inhibiting PD-1 and VEGF, while also evaluating combination strategies with antibody-drug conjugates (ADCs) across several solid tumor indications with significant unmet medical needs, including non-small cell lung cancer and colorectal cancer. Remegen Co., Ltd. is a China-based innovative biopharmaceutical company specializing in the development of RC148, a PD-1/VEGF bispecific antibody.

Major companies operating in the bispecific antibody cancer therapy market are Johnson & Johnson, F. Hoffmann-La Roche AG, Pfizer Inc., AbbVie Inc., Merck & Co. Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Sanofi S.A., GSK plc, Amgen Inc., Daiichi Sankyo Company, Regeneron Pharmaceuticals Inc., BeiGene Ltd., BioNTech SE, Jazz Pharmaceuticals plc, Genmab A/S, Summit Therapeutics Inc., Innovent Biologics Inc., Akeso Inc., NovaBridge Biosciences, Zymeworks Inc., Xencor Inc., MacroGenics Inc., Merus N.V., Compass Therapeutics Inc.

North America was the dominant region in the bispecific antibody cancer therapy market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in bispecific antibody cancer therapy report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bispecific antibody cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bispecific antibody cancer therapy market consists of revenues earned by entities by providing services such as research and development of bispecific antibodies, clinical trials, biologic drug development, immunotherapy design, and therapeutic innovation in oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. The bispecific antibody cancer therapy market also includes sales of bispecific antibody drugs, engineered biologics, monoclonal antibody platforms, recombinant protein-based therapeutics, and associated biopharmaceutical products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The bispecific antibody cancer therapy market research report is one of a series of new reports from The Business Research Company that provides bispecific antibody cancer therapy market statistics, including bispecific antibody cancer therapy industry global market size, regional shares, competitors with a bispecific antibody cancer therapy market share, detailed bispecific antibody cancer therapy market segments, market trends and opportunities, and any further data you may need to thrive in the bispecific antibody cancer therapy industry. This bispecific antibody cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bispecific Antibody Cancer Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses bispecific antibody cancer therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bispecific antibody cancer therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bispecific antibody cancer therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Mechanism: T Cell Engager; Natural Killer Cell Engagers; Checkpoint Inhibitor Bispecifics; Antibody Drug Conjugate Bispecific Hybrids
• 2) By Cancer Indication: Hematologic Malignancies; Lung Cancer; Colorectal Cancer; Prostate Cancer; Ovarian Cancer
• 3) By Format: Immunoglobulin G Like Bispecific; Fragment Based Bispecific T Cell Engager; Nanobody Based; Trispecific
• 4) By End User: Hospitals; Specialty Oncology Centers; Research And Academic Institutes; Pharmaceutical And Biotechnology Companies
• Subsegments:
• 1) By T Cell Engager: Cluster Of Differentiation 3 Redirecting Antibodies; Dual Tumor Antigen Targeting Antibodies; Immune Synapse Forming Antibodies; Hematologic Cancer Targeting Antibodies; Solid Tumor Targeting Antibodies
• 2) By Natural Killer Cell Engagers: Cluster Of Differentiation 16 Activating Antibodies; Natural Killer Group Receptor Targeting Antibodies; Cytokine Enhanced Natural Killer Cell Antibodies; Tumor Directed Natural Killer Cell Engagers; Innate Immune Activating Antibodies
• 3) By Checkpoint Inhibitor Bispecifics: Programmed Death Receptor Targeting Antibodies; Programmed Death Ligand Targeting Antibodies; Cytotoxic T Lymphocyte Associated Protein Targeting Antibodies; Lymphocyte Activation Gene Targeting Antibodies; Dual Immune Checkpoint Blocking Antibodies
• 4) By Antibody Drug Conjugate Bispecific Hybrids: Dual Payload Conjugated Antibodies; Targeted Cytotoxic Delivery Antibodies; Tumor Microenvironment Responsive Conjugates; Immune Activating Drug Conjugates; Multi Antigen Targeting Drug Conjugates
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche AG; Pfizer Inc.; AbbVie Inc.; Merck & Co. Inc.; AstraZeneca PLC; Bristol-Myers Squibb Company; Sanofi S.A.; GSK plc; Amgen Inc.; Daiichi Sankyo Company; Regeneron Pharmaceuticals Inc.; BeiGene Ltd.; BioNTech SE; Jazz Pharmaceuticals plc; Genmab A/S; Summit Therapeutics Inc.; Innovent Biologics Inc.; Akeso Inc.; NovaBridge Biosciences; Zymeworks Inc.; Xencor Inc.; MacroGenics Inc.; Merus N.V.; Compass Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.